Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Thursday, November 9, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced a late-breaking poster presentation at the AASLD Annual Meeting. The presentation will showcase their proprietary ARCUS platform, which is focused on in vivo gene editing. A webcast and conference call are scheduled for November 13, 2023, to discuss the details further.
Price reaction · baseline $11.793 (2023-11-08 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is hosting a significant presentation at AASLD.
  • The company is utilizing its innovative ARCUS platform for gene editing.
  • The event highlights the company's advancements in liver disease research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

Company to Host Webcast and Conference Call on Monday, November 13, 2023 at 4:30 PM ET DURHAM, N.C. –(BUSINESS WIRE)–Nov. 9, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing

Frequently Asked Questions

What is the focus of Precision BioSciences' presentation?

The presentation focuses on their proprietary ARCUS platform for gene editing.

When is the webcast for the AASLD presentation?

The webcast is scheduled for November 13, 2023, at 4:30 PM ET.

Where will the presentation take place?

The presentation will take place at the American Association for the Study of Liver Diseases Annual Meeting.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences AASLD gene editing ARCUS
Last updated: Nov 9, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →